Scinovex
article Open AccessTop 1% cited

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Annals of the Rheumatic Diseases · 2009 · Vol. 69(1) · pp. 88–96
Graeme JonesAnthony SebbaJianhui GuMitchell B. LowensteinAndrea CalvoJuan J. Gómez‐ReinoDaniel SiriMatija TomšičEmma AlecockThasia WoodworthM. C. Genovese

Abstract

Tocilizumab monotherapy is better than methotrexate monotherapy, with rapid improvement in RA signs and symptoms, and a favourable benefit-risk, in patients for whom treatment with methotrexate or biological agents has not previously failed.

Rheumatoid Arthritis Research and TherapiesAutoimmune and Inflammatory Disorders ResearchSystemic Lupus Erythematosus ResearchTocilizumabMedicineRheumatoid arthritisMethotrexateInternal medicineNeutropeniaRheumatologyPlaceboGastroenterologyAdverse effect

MeSH terms

AdultAgedAntibodies, MonoclonalArthritis, RheumatoidC-Reactive ProteinDouble-Blind MethodFemaleHumansImmunosuppressive AgentsMaleMethotrexateMiddle AgedSeverity of Illness IndexBiomarkersTreatment Outcome

Funding

  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • Sanofi
  • Biogen
  • Servier
  • Genentech
Citations
804
FWCI
39.91
field-weighted impact
References
44
Percentile
100%
vs. same field & year
Citations per year
References
Guidelines for the management of rheumatoid arthritis: 2002 Update
Arthritis & Rheumatism · 2002 · 1,211 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study · Scinovex